Free Delivery Over $100
|
|
|||
|
||||
OverviewOver the past decade, neuroproteomics has shed light on the molecular features of schizophrenia by depicting biological processes involved with its establishment, maintenance and treatment. These studies have also pointed to potential biomarkers applicable to diagnosis and medication monitoring. Edited by a leader in the field of neuroproteomics with contributions from subject experts, this new volume will address recent findings and compile evidence from difference perspectives—such as human samples, animal models, pluripotent stem cell-derived in vitro pre-clinical models—and provide findings to inform the development of innovative future treatment strategies. This volume will be useful for a broad audience of researchers and professionals, including biologists, neurologists, psychiatrists, analytical chemists, and pharmacists, among others. Full Product DetailsAuthor: Daniel Martins-de-SouzaPublisher: Springer Nature Switzerland AG Imprint: Springer Nature Switzerland AG Edition: 1st ed. 2022 Volume: 1400 Weight: 0.496kg ISBN: 9783030971816ISBN 10: 3030971813 Pages: 143 Publication Date: 06 August 2022 Audience: Professional and scholarly , College/higher education , Professional & Vocational , Postgraduate, Research & Scholarly Format: Hardback Publisher's Status: Active Availability: Manufactured on demand  We will order this item for you from a manufactured on demand supplier. Table of Contents1. Postmortem brains: what can proteomics tell us about the sources of schizophrenia?.- 2. What can we learn from animal models to study schizophrenia?.- 3. Modeling schizophrenia in vitro: challenges and insights on studying brain cell.- 4. Schizophrenia outside the brain.- 5. Molecular features triggered by antipsychotic medication in brain cells.- 6. Known and Unexplored Post-Translational Modification Pathways in Schizophrenia.- 7. Molecular findings guiding the modulation of the endocannabinoid system as a potential target to treat schizophrenia.- 8. Metabolomics: A powerful tool to understand the schizophrenia biology.- 9. Modulating specific pathways in vitro to understand the synaptic dysfunction of schizophrenia.- 10. Proteomics and schizophrenia: the evolution of a great partnership.ReviewsAuthor InformationDaniel Martins-de-Souza holds a PhD in Biochemistry and Molecular Biology and is an Associate Professor of Biochemistry and Head of Proteomics at the University of Campinas (UNICAMP), in Brazil. Daniel´s postdoctoral training was carried out in the Max Planck Institute of Psychiatry in Germany and at the University of Cambridge, in the UK. For two years, Daniel was Principal Investigator in the Dept. of Psychiatry and Psychotherapy of the Ludwig Maximilians University (LMU), just before becoming a Professor. Daniel was elected Affiliated Member of the São Paulo Academy of Sciences in 2019 and Affiliated Member of the Brazilian Academy of Sciences in 2017. He is part of the Editorial Board of seven indexed journals and Associate Editor for npj Schizophrenia. His main expertise is on proteomics and systems biology tools to investigate molecular mechanisms involved in mental disorders. Tab Content 6Author Website:Countries AvailableAll regions |
||||
